

Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Cancelled)

Claim 2 (Previously presented): The composition of claim 22 characterised in that the weight ratios of drug compound to acid and of drug compound to cyclodextrin are no more than 2:1.

Claim 3 (Cancelled)

Claim 4 (Previously presented): The composition of claim 22 wherein the cyclodextrin is 2-hydroxypropyl- β -cyclodextrin.

Claim 5 (Previously presented): The composition of claim 22 wherein the acid is selected from the group comprising citric, fumaric, tartaric, maleic, malic, succinic, oxalic, malonic, benzoic, mandelic and ascorbic acid.

Claim 6 (Original): The composition of claim 5 wherein the acid is citric acid.

Claim 7 (Previously presented): The composition of claim 22 wherein the polymer is selected from the group comprising

- alkylcelluloses such as methylcellulose,
- hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose,
- hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose,
- carboxyalkylcelluloses such as carboxymethylcellulose,
- alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose,
- carboxyalkylalkylcelluloses such as carboxymethylethylcellulose,
- carboxyalkylcellulose esters,
- starches,
- pectins such as sodium carboxymethylamylopectin,

- chitin derivatives such as chitosan,
- heparin and heparinoids,
- polysaccharides such as alginic acid, alkali metal and ammonium salts thereof, carrageenans, galactomannans, tragacanth, agar-agar, gum arabic, guar gum and xanthan gum,
- polyacrylic acids and the salts thereof,
- polymethacrylic acids and the salts thereof, methacrylate copolymers,
- polyvinylalcohol,
- polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate,
- polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide, e.g. poloxamers and poloxamines.

Claim 8 (Original): The composition of claim 7 wherein the polymer has an apparent viscosity of 1-100 mPa.s when dissolved in a 2% aqueous solution at 20°C.

Claim 9 (Original): The composition of claim 8 wherein the polymer is hydroxypropylmethylcellulose.

Claim 10 (Previously presented): The composition of claim 22 wherein the drug is a basic compound.

Claim 11 (Previously presented): A composition according to claim 22 that dissolves rapidly in body fluids, characterized in that it comprises from 50 to 95 % by weight of acid.

Claim 12 (Previously presented): A composition according to claim 22 that provides sustained release of the drug, characterized in that it comprises a water soluble polymer having an apparent viscosity of more than 1,000 mPa.s when dissolved in a 2% aqueous solution at 20°C.

Claim 13 (Previously presented): A pharmaceutical dosage form comprising a therapeutically effective amount of a pharmaceutical composition as defined in claim 22.

Claim 14 (Original): The dosage form of claim 13 adapted for topical administration or administration into an externally voiding body cavity such as the nose, lungs, mouth, ear, stomach, rectum and vagina.

Claim 15 (Original): The dosage form of claim 13 wherein said composition is filled into a standard capsule, or alternatively is mixed with bulking agents and compressed into tablets.

Claim 16 (Original): The dosage form of claim 13, characterised in that at 5, 15, and 45 minutes after addition of said dosage form to 0.1N hydrochloric acid at 37°C in the dissolution test set forth in USP test <711> in a USP-2 dissolution apparatus equipped with a paddle, from 7 to 25%, 45 to 70% and at least 96% respectively of drug is dissolved in said 0.1 N hydrochloric acid.

Claim 17 (Cancelled)

Claim 18 (Cancelled)

Claim 19 (Cancelled)

Claim 20 (Previously presented): A method of therapy or diagnosis of the human or non-human animal body which comprises administering to said body a therapeutically or diagnostically effective dose of a pharmaceutical composition according to claim 22.

Claim 21 (Cancelled)

Claim 22 (Currently amended): A solid pharmaceutical composition comprising by weight 0.001 to 50% of a sparingly water-soluble drug compound, 5 to 70% of a cyclodextrin, 35 to ~~95~~ 60% of a physiologically tolerable water-soluble acid, and 0.05 to 35% of a physiologically tolerable water-soluble organic polymer characterized in that at 5, 15 and 45 minutes after addition of a quantity of the composition containing 100 mg of drug to 600 ml of 0.1 N HCl at 37°C from 7 to 25%, from 45 to 70% and at least 96% of drug is in solution.